Kyverna Therapeutics Poised for 308% Gain after Early Trial Data
Kyverna Therapeutics trades at $7.26 with consensus price targets of $29.60, implying 308% upside. Its lead candidate KYV-101 is advancing in late-stage trials for stiff-person syndrome and myasthenia gravis, with topline stiff-person syndrome data delivered ahead of schedule.
1. Analyst Upside Projection
Analysts value Kyverna Therapeutics at $29.60 per share, implying a 308% gain from its current $7.26 trading level and signaling strong conviction in its pipeline. All covering analysts maintain unanimous Buy ratings on the company.
2. KYV-101 Clinical Development
The lead CAR T-cell therapy candidate, KYV-101, is in late-stage trials for stiff-person syndrome and myasthenia gravis, with topline results for stiff-person syndrome delivered ahead of schedule. Upcoming myasthenia gravis data are expected to serve as the next major catalyst.